

# Angela Vidal-Jordana

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/5874851/publications.pdf>

Version: 2024-02-01

68  
papers

3,300  
citations

218381

26  
h-index

155451

55  
g-index

73  
all docs

73  
docs citations

73  
times ranked

4307  
citing authors

#	ARTICLE	IF	CITATIONS
1	Defining high, medium and low impact prognostic factors for developing multiple sclerosis. <i>Brain</i> , 2015, 138, 1863-1874.	3.7	403
2	Retinal layer segmentation in multiple sclerosis: a systematic review and meta-analysis. <i>Lancet Neurology</i> , The, 2017, 16, 797-812.	4.9	397
3	Multiple sclerosis: clinical aspects. <i>Current Opinion in Neurology</i> , 2018, 31, 752-759.	1.8	324
4	Radiologically Isolated Syndrome: 5-Year Risk for an Initial Clinical Event. <i>PLoS ONE</i> , 2014, 9, e90509.	1.1	254
5	Treatment of multiple sclerosis " success from bench to bedside. <i>Nature Reviews Neurology</i> , 2019, 15, 53-58.	4.9	239
6	Neurofilament light chain and oligoclonal bands are prognostic biomarkers in radiologically isolated syndrome. <i>Brain</i> , 2018, 141, 1085-1093.	3.7	115
7	COVID-19 in multiple sclerosis patients: susceptibility, severity risk factors and serological response. <i>European Journal of Neurology</i> , 2021, 28, 3384-3395.	1.7	111
8	The value of oligoclonal bands in the multiple sclerosis diagnostic criteria. <i>Brain</i> , 2018, 141, 1075-1084.	3.7	98
9	Early brain pseudoatrophy while on natalizumab therapy is due to white matter volume changes. <i>Multiple Sclerosis Journal</i> , 2013, 19, 1175-1181.	1.4	93
10	Neurofilament light chain level is a weak risk factor for the development of MS. <i>Neurology</i> , 2016, 87, 1076-1084.	1.5	85
11	Spinal cord lesions: A modest contributor to diagnosis in clinically isolated syndromes but a relevant prognostic factor. <i>Multiple Sclerosis Journal</i> , 2018, 24, 301-312.	1.4	79
12	Disability progression markers over 6 "12 %years in interferon- $\beta$ -treated multiple sclerosis patients. <i>Multiple Sclerosis Journal</i> , 2018, 24, 322-330.	1.4	60
13	Brain atrophy in natalizumab-treated patients: A 3-year follow-up. <i>Multiple Sclerosis Journal</i> , 2015, 21, 749-756.	1.4	51
14	Multiple Sclerosis. <i>Neuroimaging Clinics of North America</i> , 2017, 27, 195-204.	0.5	51
15	Menarche, pregnancies, and breastfeeding do not modify long-term prognosis in multiple sclerosis. <i>Neurology</i> , 2019, 92, e1507-e1516.	1.5	49
16	Significant clinical worsening after natalizumab withdrawal: Predictive factors. <i>Multiple Sclerosis Journal</i> , 2015, 21, 780-785.	1.4	43
17	Contribution of the symptomatic lesion in establishing MS diagnosis and prognosis. <i>Neurology</i> , 2016, 87, 1368-1374.	1.5	42
18	Statin pretreatment may increase the risk of symptomatic intracranial haemorrhage in thrombolysis for ischemic stroke: results from a case-control study and a meta-analysis. <i>Journal of Neurology</i> , 2012, 259, 111-118.	1.8	41

#	ARTICLE	IF	CITATIONS
19	The long-term outcomes of CIS patients in the Barcelona inception cohort: Looking back to recognize aggressive MS. <i>Multiple Sclerosis Journal</i> , 2020, 26, 1658-1669.	1.4	41
20	SIGLEC1 and SIGLEC7 expression in circulating monocytes of patients with multiple sclerosis. <i>Multiple Sclerosis Journal</i> , 2013, 19, 524-531.	1.4	38
21	Effect of Changes in MS Diagnostic Criteria Over 25 Years on Time to Treatment and Prognosis in Patients With Clinically Isolated Syndrome. <i>Neurology</i> , 2021, 97, e1641-e1652.	1.5	35
22	Treating relapsingâ€“remitting multiple sclerosis: therapy effects on brain atrophy. <i>Journal of Neurology</i> , 2015, 262, 2617-2626.	1.8	34
23	Retinal inner nuclear layer volume reflects inflammatory disease activity in multiple sclerosis; a longitudinal OCT study. <i>Multiple Sclerosis Journal - Experimental, Translational and Clinical</i> , 2019, 5, 205521731987158.	0.5	34
24	Prognostic impact of total metabolic tumor volume in large B-cell lymphoma patients receiving CAR T-cell therapy. <i>Annals of Hematology</i> , 2021, 100, 2303-2310.	0.8	32
25	Optic Nerve Topography in Multiple Sclerosis Diagnosis. <i>Neurology</i> , 2021, 96, e482-e490.	1.5	32
26	Predictive value of early brain atrophy on response in patients treated with interferon Î². <i>Neurology: Neuroimmunology and NeuroInflammation</i> , 2015, 2, e132.	3.1	28
27	Lesion topographies in multiple sclerosis diagnosis. <i>Neurology</i> , 2017, 89, 2351-2356.	1.5	27
28	Role of high mobility group box protein 1 (HMGB1) in peripheral blood from patients with multiple sclerosis. <i>Journal of Neuroinflammation</i> , 2015, 12, 48.	3.1	26
29	Exome sequencing study in patients with multiple sclerosis reveals variants associated with disease course. <i>Journal of Neuroinflammation</i> , 2018, 15, 265.	3.1	25
30	Risk Acceptance in Multiple Sclerosis Patients on Natalizumab Treatment. <i>PLoS ONE</i> , 2013, 8, e82796.	1.1	23
31	Brain Volume Loss During the First Year of Interferonâ€“Beta Treatment in Multiple Sclerosis: Baseline Inflammation and Regional Brain Volume Dynamics. <i>Journal of Neuroimaging</i> , 2016, 26, 532-538.	1.0	21
32	Grey matter atrophy is associated with disability increase in natalizumab-treated patients. <i>Multiple Sclerosis Journal</i> , 2017, 23, 556-566.	1.4	21
33	Optical coherence tomography measures correlate with brain and spinal cord atrophy and multiple sclerosis diseaseâ€“related disability. <i>European Journal of Neurology</i> , 2020, 27, 2225-2232.	1.7	20
34	The frequency and characteristics of MS misdiagnosis in patients referred to the multiple sclerosis centre of Catalonia. <i>Multiple Sclerosis Journal</i> , 2021, 27, 913-921.	1.4	20
35	Natalizumab discontinuation after PML risk stratification: outcome from a shared and informed decision. <i>Multiple Sclerosis Journal</i> , 2012, 18, 1193-1196.	1.4	19
36	An uncommon first manifestation of multiple sclerosis: Tako-Tsubo cardiomyopathy. <i>Multiple Sclerosis Journal</i> , 2016, 22, 842-846.	1.4	18

#	ARTICLE	IF	CITATIONS
37	Humoral and Cellular Responses to SARS-CoV-2 in Convalescent COVID-19 Patients With Multiple Sclerosis. <i>Neurology: Neuroimmunology and NeuroInflammation</i> , 2022, 9, e1143.	3.1	17
38	Value of NMO-IgG determination at the time of presentation as CIS. <i>Neurology</i> , 2012, 78, 1608-1611.	1.5	16
39	Chitinase 3-like 1 is associated with the response to interferon-beta treatment in multiple sclerosis. <i>Journal of Neuroimmunology</i> , 2017, 303, 62-65.	1.1	16
40	Menopause does not modify disability trajectories in a longitudinal cohort of women with clinically isolated syndrome and multiple sclerosis followed from disease onset. <i>European Journal of Neurology</i> , 2022, 29, 1075-1081.	1.7	16
41	Deciphering Multiple Sclerosis Progression. <i>Frontiers in Neurology</i> , 2021, 12, 608491.	1.1	16
42	Simultaneous CMV and <i>Listeria</i> infection following alemtuzumab treatment for multiple sclerosis. <i>Neurology</i> , 2019, 92, 296-298.	1.5	15
43	CSF Chitinase 3 Like 2 Is Associated With Long-term Disability Progression in Patients With Progressive Multiple Sclerosis. <i>Neurology: Neuroimmunology and NeuroInflammation</i> , 2021, 8, .	3.1	15
44	Circulating levels of soluble apoptosis-related molecules in patients with multiple sclerosis. <i>Journal of Neuroimmunology</i> , 2013, 263, 152-154.	1.1	13
45	Assessing and mitigating risk of infection in patients with multiple sclerosis on disease modifying treatment. <i>Expert Review of Clinical Immunology</i> , 2021, 17, 285-300.	1.3	12
46	Natalizumab-related anaphylactoid reactions in MS patients are associated with HLA class II alleles. <i>Neurology: Neuroimmunology and NeuroInflammation</i> , 2014, 1, e47.	3.1	11
47	Is humoral and cellular response to SARS-CoV-2 vaccine modified by DMT in patients with multiple sclerosis and other autoimmune diseases?. <i>Multiple Sclerosis Journal</i> , 2022, 28, 1138-1145.	1.4	11
48	Should we systematically test patients with clinically isolated syndrome for auto-antibodies?. <i>Multiple Sclerosis Journal</i> , 2015, 21, 1802-1810.	1.4	10
49	A validation study of manual atrophy measures in patients with Multiple Sclerosis. <i>Neuroradiology</i> , 2020, 62, 955-964.	1.1	10
50	Treatment response scoring systems to assess long-term prognosis in self-injectable DMTs relapsing-remitting multiple sclerosis patients. <i>Journal of Neurology</i> , 2022, 269, 452-459.	1.8	10
51	Measurement of Cortical Thickness and Volume of Subcortical Structures in Multiple Sclerosis: Agreement between 2D Spin-Echo and 3D MPRAGE T1-Weighted Images. <i>American Journal of Neuroradiology</i> , 2017, 38, 250-256.	1.2	9
52	Activation-induced cell death in T lymphocytes from multiple sclerosis patients. <i>Journal of Neuroimmunology</i> , 2014, 272, 51-55.	1.1	8
53	Levels of soluble TNF-RII are increased in serum of patients with primary progressive multiple sclerosis. <i>Journal of Neuroimmunology</i> , 2014, 271, 56-59.	1.1	7
54	New Advances in Disease-Modifying Therapies for Relapsing and Progressive Forms of Multiple Sclerosis. <i>Neurologic Clinics</i> , 2018, 36, 173-183.	0.8	7

#	ARTICLE	IF	CITATIONS
55	Oral contraceptives do not modify the risk of a second attack and disability accrual in a prospective cohort of women with a clinically isolated syndrome and early multiple sclerosis. <i>Multiple Sclerosis Journal</i> , 2022, 28, 950-957.	1.4	7
56	Brain atrophy 15 years after CIS: Baseline and follow-up clinico-radiological correlations. <i>Multiple Sclerosis Journal</i> , 2018, 24, 721-727.	1.4	6
57	TRPM4 mRNA expression levels in peripheral blood mononuclear cells from multiple sclerosis patients. <i>Journal of Neuroimmunology</i> , 2013, 261, 146-148.	1.1	5
58	Identification of patients with relapsing multiple sclerosis eligible for high-efficacy therapies. <i>Neurodegenerative Disease Management</i> , 2021, 11, 251-261.	1.2	5
59	Impact of COVID-19 pandemic on frequency of clinical visits, performance of MRI studies, and therapeutic choices in a multiple sclerosis referral centre. <i>Journal of Neurology</i> , 2022, 269, 1764-1772.	1.8	5
60	Assessment of automatic decision-support systems for detecting active T2 lesions in multiple sclerosis patients. <i>Multiple Sclerosis Journal</i> , 2022, 28, 1209-1218.	1.4	4
61	Characteristics of morphologic macular abnormalities in neuroimmunology practice. <i>Multiple Sclerosis Journal</i> , 2019, 25, 361-371.	1.4	2
62	Adding brain volume measures into response criteria in multiple sclerosis: the R <sup>2</sup> -4 score. <i>Neuroradiology</i> , 2021, 63, 1031-1041.	1.1	2
63	Neurotoxicity-associated sinus bradycardia after chimeric antigen receptor T-cell therapy. <i>Hematological Oncology</i> , 2022, , .	0.8	2
64	Spinal cord grey matter atrophy in Multiple Sclerosis clinical practice. <i>Neuroscience Informatics</i> , 2022, 2, 100071.	2.8	1
65	Comment on "Isolated bilateral horizontal gaze palsy as first manifestation of multiple sclerosis" by Stefan Kipfer and David W Crook. <i>Multiple Sclerosis Journal</i> , 2014, 20, 756-756.	1.4	0
66	Comment on: "Prevalence of brain magnetic resonance imaging meeting Barkhof and McDonald criteria for dissemination in space among headache patients". <i>Multiple Sclerosis Journal</i> , 2014, 20, 897-898.	1.4	0
67	Prognostic Impact of Metabolic Tumor Burden in Large B-Cell Lymphoma Patients Receiving CAR T-Cell Therapy. <i>Blood</i> , 2020, 136, 27-29.	0.6	0
68	Can Cognitive training Reignite Compensatory Mechanisms in Advanced Multiple Sclerosis Patients? An Explorative Morphological Network Approach. <i>Neuroscience</i> , 2022, , .	1.1	0